Contemporary Trends in Malignant Peritoneal Mesothelioma: Incidence and Survival in the United States
Authors:
- Lucia CalthorpeLCLucia Calthorpe
- Fernanda Romero-HernandezFRFernanda Romero-Hernandez
- Phoebe MillerPMPhoebe Miller
- Patricia C. ConroyPCPatricia C. Conroy
- Kenzo HiroseKHKenzo Hirose
- Alex KimAKAlex Kim
- Kimberly KirkwoodKKKimberly Kirkwood
- Eric NakakuraENEric Nakakura
- Carlos CorveraCCCarlos Corvera
- Ajay V. MakerAMAjay V. Maker
- Adnan AlseidiAAAdnan Alseidi
- Mohamed Abdelgadir AdamMAMohamed Abdelgadir Adam
Open Access
Abstract
Background: Malignant peritoneal mesothelioma (MPM) is a rare disease with a historically poor prognosis. Given the emergence of effective therapies, a contemporary analysis of MPM incidence and survival is warranted. Methods: The SEER-18 registry dataset was analyzed (2000–2018). Age-adjusted annual incidence was stratified by sex and histology. Joinpoint regression was used to estimate annual percent change (APC) in incidence. Multivariable cox proportional hazards models were used to investigate survival trends. Results: Of 1689 MPM cases, most were male (55.4%), >50 years (80.0%), and white (75.2%). Age-adjusted incidence of MPM remained stable over time, with an average annual incidence of 1.02 cases/million. Epithelioid histology increased by 240% (APC 2.6; 95% CI: 0.7, 4.5), while incidence of undefined histology decreased significantly (APC −2.1; 95% CI: −3.1, −1.1). Cases treated with cancer-directed surgery increased from 27% to 43%. Overall median age-standardized survival was 11.6 months. Median age-standardized survival was 16.6 months for epithelioid histology but 2.0 months for sarcomatoid histology. Diagnosis in recent years (2015–2018 HR 0.51; 95% CI: 0.38, 0.67) and receipt of cancer-directed surgery (HR 0.84; 95% CI: 0.72, 0.98) were associated with improved survival. Conclusions: Although the overall incidence of MPM remained stable, recognition of epithelioid histology increased. Concurrent with an increase in cancer-directed surgery, MPM survival has improved.Keywords
This publication has 29 references indexed in Scilit:
- Cytoreductive Surgery with Selective Versus Complete Parietal Peritonectomy Followed by Hyperthermic Intraperitoneal Chemotherapy in Patients with Diffuse Malignant Peritoneal Mesothelioma: A Controlled StudyAnnals of Surgical Oncology, 2012
- Rare cancers are not so rare: The rare cancer burden in EuropeEuropean Journal of Cancer, 2011
- Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional ExperienceJournal of Clinical Oncology, 2009
- Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973–2005Cancer Causes & Control, 2009
- Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conferenceAnnals of Oncology, 2006
- Advances in Malignant MesotheliomaNew England Journal of Medicine, 2005
- Malignant Mesothelioma and Occupational Exposure to Asbestos: A Clinicopathological Correlation of 1445 CasesUltrastructural Pathology, 2002
- The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposureAnnals of Occupational Hygiene, 2000
- Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systemsThorax, 2000
- Malignant mesothelioma: attributable risk of asbestos exposure.Occupational and Environmental Medicine, 1994